| Budget Amount *help |
¥90,870,000 (Direct Cost: ¥69,900,000、Indirect Cost: ¥20,970,000)
Fiscal Year 2020: ¥16,900,000 (Direct Cost: ¥13,000,000、Indirect Cost: ¥3,900,000)
Fiscal Year 2019: ¥16,900,000 (Direct Cost: ¥13,000,000、Indirect Cost: ¥3,900,000)
Fiscal Year 2018: ¥16,900,000 (Direct Cost: ¥13,000,000、Indirect Cost: ¥3,900,000)
Fiscal Year 2017: ¥16,900,000 (Direct Cost: ¥13,000,000、Indirect Cost: ¥3,900,000)
Fiscal Year 2016: ¥23,270,000 (Direct Cost: ¥17,900,000、Indirect Cost: ¥5,370,000)
|
|---|
| Outline of Final Research Achievements |
To comprehensively analyze the function of TCRs that are obtained by neo-self-reactive receptor repertoire analysis, we have developed cFIT method and TAP-J method. By using these methods, we have identified various TCRs reacting to self-antigen, tumor cells, or foreign antigen. We have also developed the easy protocol to prepare soluble MHC/peptide complex using animal cells, which un-require refolding of proteins. By using soluble MHC/peptide complex prepared by the method, we have prepared TCR-like antibodies that recognize MHC/peptide complex as TCR does. Furthermore, we have performed many collaborations with researchers in and outside of the innovative area.
|
